The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Distinct Autoantigens Found in Patients with Scleroderma & Coincident Cancer

Distinct Autoantigens Found in Patients with Scleroderma & Coincident Cancer

January 24, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients with scleroderma can have a wide range of autoantigens, and distinct autoantigen profiles seem to correlate with a specific course of disease. Scleroderma is most frequently associated with the autoantibodies, anti-centromere, anti-topoisomerase 1 and anti-RNA polymerase III (anti-POLR3). Patients with all three of these autoantibodies can be described as anti-CTP antibody positive. Some patients with scleroderma are also anti-CTP antibody negative. Often, these individuals rapidly go on to develop cancer. The details of their autoimmune response and its relationship to cancer remain unknown.

You Might Also Like
  • Scleroderma Autoantibodies Linked to Cancer Risk
  • Can Scleroderma Be Cured by Curing Cancer?
  • From the Expert: Insight into the Intersection of Cancer & Autoimmunity
Also By This Author
  • SLE—It’s in the Genes

George J. Xu, PhD, a graduate student at Harvard University in Cambridge, Mass., and colleagues addressed this knowledge gap with their analysis of intramolecular epitope spreading in patients with scleroderma. Their precision medicine approach allowed them to meet the challenges presented by a complex autoimmune response. They published the results online last November in the Proceedings of the National Academy of Sciences.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“To address these issues, we have developed and used two high throughput epitope identification methods to identify immunological characteristics of different subclasses of scleroderma (POLR3-positive scleroderma with cancer, POLR3-positive scleroderma without cancer and patients with cancer-associated scleroderma who are anti-CTP–negative),” write the authors in their discussion. “Our methods included a significantly improved version of PLATO [parallel analysis of translated ORFs], PLATO-BC, which greatly simplifies the original assay, which was not compatible with high-throughput applications.” The investigators combined a bar-coded whole-genome ORF mRNA display library with phage-immunoprecipitation sequencing (PhIP-Seq). They used the approach to analyze sera from patients with scleroderma with or without known autoantibody specificities.

The researchers were able to successfully identify the POLR3 complex in cancer-associated scleroderma using PhIP-Seq. They also found notable intermolecular spreading among subunits of the POLR3 complex. Approximately one-quarter of patients with scleroderma and cancer did not have antibodies to CTP, but did have autoantibodies against the minor spliceosome complex. These patients had autoantibodies to RNA Binding Region (RNP1, RNA recognition motif) Containing 3 (RNPC3), as well as various other components of the minor spliceosome. This specificity was absent in unrelated autoimmune diseases. The investigators also found intra- and intermolecular epitope spreading within RNPC3 and the complex.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Our results demonstrate the benefit of combining the two complementary approaches, PhIP-Seq and PLATO-BC, for identifying autoantibody specificities in large, heterogeneous populations,” explained the authors. “These methods have complementary strengths and weaknesses. Although PhIP-Seq has the advantages of being high throughput, identifying individual epitopes, detecting intraprotein epitope spreading and possessing a complete representation of the human proteome, it does not identify all patients with a particular specificity (e.g., POLR3A), possibly due to its reduced ability to detect a portion of antibodies that recognize discontinuous epitopes.”

Pages: 1 2 | Single Page

Filed Under: Conditions, Scleroderma

You Might Also Like:
  • Scleroderma Autoantibodies Linked to Cancer Risk
  • Can Scleroderma Be Cured by Curing Cancer?
  • From the Expert: Insight into the Intersection of Cancer & Autoimmunity
  • Stem Cell Transplantation Benefits Patients with Scleroderma

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.